Contact
![Contact Meredith Alda](https://cdn.statcdn.com/contactPerson/3646.jpg)
Mon - Fri, 9am - 6pm (EST)
![Contact Yolanda Mega](https://cdn.statcdn.com/contactPerson/3195.jpg)
Mon - Fri, 9am - 5pm (SGT)
![Contact Kisara Mizuno](https://cdn.statcdn.com/contactPerson/2661.jpg)
Mon - Fri, 10:00am - 6:00pm (JST)
![Contact Lodovica Biagi](https://cdn.statcdn.com/contactPerson/863.jpg)
Mon - Fri, 9:30am - 5pm (GMT)
![Contact Carolina Dulin](https://cdn.statcdn.com/contactPerson/3012.jpg)
Mon - Fri, 9am - 6pm (EST)
Key regions: Japan, India, Italy, Brazil, South Korea
Montenegro, a small country located in Southeast Europe, has been experiencing a steady growth in the Anti-Hypertensive Drugs market.
Customer preferences: Montenegro's population has been aging, leading to an increase in the prevalence of hypertension. As a result, the demand for Anti-Hypertensive Drugs has been rising. Additionally, the country's healthcare system has been improving, leading to better access to healthcare for the population.
Trends in the market: The market has been dominated by the sales of generic drugs due to their affordability and availability. However, there has been an increase in the demand for branded drugs due to their perceived higher quality. The market has also been witnessing an increase in the adoption of combination therapies, which offer better efficacy in the treatment of hypertension.
Local special circumstances: Montenegro's healthcare system is primarily funded by the government, which has been investing in the healthcare infrastructure and services. However, the country's healthcare spending per capita remains low compared to other European countries. This has led to a reliance on generic drugs, which are more affordable for the population.
Underlying macroeconomic factors: Montenegro's economy has been growing steadily, with a focus on tourism and foreign investment. The country's accession to the European Union is also expected to boost the economy. However, the country still faces challenges such as high unemployment rates and a large informal economy. These factors may impact the affordability of healthcare for the population, leading to a continued reliance on generic drugs in the Anti-Hypertensive Drugs market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)